ArticlePharmacy (Basel, Switzerland)2019
Diabetes Screening Through Community Pharmacies in England: A Cost-Effectiveness Study.
Article in Pharmacy (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Decision models in type 2 diabetes mellitus: A systematic review.Acta diabetologica · 2021Pooled it
- Article
- Diabetes risk assessment in Polish community pharmacies. Results from a pilot national screening campaign.Archives of medical science : AMS · 2026Article
- Improving Diabetes and Pre-Diabetes Detection in the UK: Insights From HbA1c Screening in an Acute Hospital's Emergency Department.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Cost-effectiveness analysis of a community pharmacist-based intervention to prevent cardiovascular complications in patients with type 2 diabetes in Iran.Cost effectiveness and resource allocation : C/E · 2025Article
- Leveraging Dental Visits for Systemic Health: Diabetes Screening and Referral Compliance in Periodontitis Patients in Malaysia.Journal of clinical medicine · 2025Article
- Implementation of point-of-care HbA1C instruments into community pharmacies: Initial development of a pathway for robust community testing.Annals of clinical biochemistry · 2024Article
- Feasibility of a Type 2 Diabetes Prevention Program at Nationwide Level in General Practice: A Pilot Study in Italy.Journal of clinical medicine · 2024Article
- Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran.Research in pharmaceutical sciences · 2023Article
- Diabetes and Cardiovascular Diseases Risk Assessment in Community Pharmacies: An Implementation Study.International journal of environmental research and public health · 2022Article
- Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis.BMC health services research · 2021Article
- Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases.Patient preference and adherence · 2021Article
- A cross-sectional look at rural pharmacists' perceptions on implementing a depression screening service in their pharmacies: A brief report.Journal of the American Pharmacists Association : JAPhAArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Community pharmacies are commonly used to screen for patients with diabetes. The aim of this paper is to estimate the cost per test and cost per appropriately referred patient from a pharmacy perspective using a one-year decision tree model. One-way sensitivity analysis was performed to estimate the effect of geographical location and patient self-referral rate. Data was used from 164 patients screened and located in an area with average social deprivation and largely white European inhabitants and 172 patients in an area with higher social deprivation (lower than average ability to access society's resources) and a mixed ethnicity population in England. The diabetes screening consisted of initial risk assessment via questionnaire followed by HbA1c test for those identified as high risk. The cost per person screened was estimated as £28.65. The cost per appropriately referred patient with type 2 diabetes was estimated to range from £7638 to £11,297 in deprived mixed ethnicity and non-deprived areas respectively. This increased to £12,730 and £18,828, respectively, if only 60% of patients referred chose to inform their general practitioner (GP). The cost per test and identification rates through community pharmacies was similar to that reported through medical practices. Locating services in areas of suspected greater diabetes prevalence and increasing the proportion of patients who follow pharmacist advice to attend their medical practice improves cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.